
Two Onc Docs
This is Sam and Karine, and we are Two Onc Docs! We both graduated from our Heme/Onc fellowships in 2021 and became board certified in both Hematology and Oncology. Our mission with Two Onc Docs is to create short board review episodes that you can listen to on your drive to work, while you make your morning coffee, or between pages on call. This is intended to be a supplement to other established board studying resources for busy trainees. *This podcast is intended to be an educational resource for health care providers.*
Latest episodes

Jan 20, 2025 • 24min
Small Cell Lung Cancer 2025 x Dr. Stephen Liu Part 1
Dr. Stephen Liu, an international lung cancer expert and Director of Thoracic Oncology at Georgetown Lombardi Cancer Center, dives into the complexities of Small Cell Lung Cancer (SCLC). He discusses the impact of smoking and emerging cases among non-smokers. The conversation covers essential staging methods and effective treatment strategies, emphasizing immunotherapy breakthroughs from recent studies. Liu also explores the integration of immunotherapy with chemotherapy and its promising yet gradual outcomes, shedding light on the evolving landscape of lung cancer treatment.

Jan 15, 2025 • 12min
Polycythemia Vera 2025
Dive into the complexities of Polycythemia Vera, a condition characterized by excessive red blood cell production. Learn about the critical JAK-STAT pathway and its mutations that influence treatment decisions. Discover how to differentiate between primary and secondary forms of the disease through essential blood tests. Explore targeted strategies for managing high and low-risk patients, including the use of aspirin, hydroxyurea, and recent clinical trials. Special considerations for unique populations, like pregnant patients, round out this informative discussion.

Jan 6, 2025 • 18min
Immune Related Adverse Events (irAEs)
The hosts dive into the fascinating world of immune checkpoint inhibitors and their impact on cancer treatment. They discuss the mechanisms behind immunotherapy and the rise of immune-related adverse events (irAEs). Key management strategies for common side effects are explored, including dermatologic and gastrointestinal reactions. The conversation highlights the importance of patient education and the need for coordinated care with specialists to handle challenging toxicities, especially for those with autoimmune histories.

Dec 16, 2024 • 20min
Thymoma x Dr. Pat Loehrer Part 2
This week features Dr. Pat Loehrer, a renowned expert in thymoma treatment, sharing his vast knowledge. He dives into advanced treatment strategies for thymoma and thymic carcinoma, emphasizing the importance of preoperative chemotherapy. Dr. Loehrer also discusses the significance of genomic testing for targeted therapies and shares valuable career advice for early-career oncologists. He reflects on the importance of mentorship and the evolving landscape of thymoma research, creating an enlightening session for aspiring medical professionals.

Dec 9, 2024 • 23min
Thymoma x Dr. Pat Loehrer Part 1
Dr. Pat Loehrer, a Distinguished Professor of Medicine and an expert in thymoma treatment, delves into localized thymoma and thymic carcinoma. He discusses the intriguing connection between thymomas and autoimmune disorders, especially myasthenia gravis. The talk covers the rarity of thymic tumors, survival rates, and the distinctive characteristics of various thymoma subtypes. Dr. Loehrer also highlights the importance of staging, surgical techniques, and the role of multidisciplinary teams in managing these unique cancers.

Nov 25, 2024 • 21min
Metastatic Non-Small Cell Lung Cancer 2024 UPDATE
Dr. Jennifer Marks, a Thoracic Oncologist at the Dana-Farber Cancer Institute, dives deep into metastatic non-small cell lung cancer. She highlights the rapidly evolving systemic therapy options, including traditional chemotherapy and cutting-edge immunotherapies. The discussion emphasizes the critical role of PD-L1 testing in treatment decisions and the impact of key mutations like EGFR and HER2 on targeted therapies. Listeners learn about the latest FDA approvals and strategies for managing treatment-related side effects, showcasing the dynamic landscape of lung cancer treatment.

Nov 18, 2024 • 25min
Localized Non-Small Cell Lung Cancer 2024 UPDATE
Dr. Jennifer Marks, a thoracic oncologist at Dana-Farber Cancer Institute and Harvard medical instructor, dives deep into localized non-small cell lung cancer (NSCLC). She discusses the latest on staging using the TNM classification and treatment strategies for both resectable and unresectable cases. Key highlights include the impact of the PACIFIC trial and innovative adjuvant chemotherapy approaches. Dr. Marks emphasizes the integration of molecular testing and multidisciplinary care to enhance patient outcomes, shedding light on evolving standards in oncology.

Nov 11, 2024 • 20min
Hemoglobin Electrophoresis
Dive into the fascinating world of hemoglobin electrophoresis, where various types of hemoglobin are separated with electric currents. Explore the nuances of disorders like thalassemia and sickle cell disease, including their diagnostic implications. Discover how alpha thalassemias affect test results and the challenges they pose for newborns. Learn about unique variants such as hemoglobin E and Lepore, and gain valuable study tips for hematology exams. It's a must-listen for anyone interested in understanding the complexities of hemoglobinopathies!

Oct 28, 2024 • 26min
Special Guest: CRC Survivor & Patient Advocate Marisa Peters
In honor of National Family Health History Month in November, we have a special guest. We share the story of an incredible colorectal cancer survivor and health advocate, Marisa Peters, who was a Broadway vocalist and a very healthy, active mom to 3 young boys, yet diagnosed with stage 3 rectal cancer at only 39 years old.

Oct 21, 2024 • 20min
Metastatic Breast Cancer 2024 UPDATE
Dr. Eleonora Teplinsky, a board-certified oncologist specializing in breast and gynecologic oncology, shares vital updates on metastatic breast cancer treatment. Dive into the latest systemic therapies for ER-positive cases, including endocrine therapy and CDK4-6 inhibitors. Discover new strategies for premenopausal women and the use of triplet therapy for PIK3CA mutations. Learn about advancements in HER2-positive patients with innovative drugs and the importance of molecular testing. Gain insights into managing toxicities and enhancing patient care.